POWER ASSETS (00006) announced its interim results, with a profit attributable to shareholders of HK$14.704 billion, an increase of 383.37% year-on-year.
Electric Power Industry (00006) announced its mid-term results for 2026, with the group achieving revenue of HKD 298 million, a decrease of 15.34% year-on-year; the profit attributable to shareholders was HKD 14.704 billion, an increase of 383.37% year-on-year; earnings per share were HKD 6.9, and an interim dividend of HKD 0.78 per share is proposed.
POWER ASSETS (00006) announced its mid-term results for 2026, reporting revenue of HK$298 million, a year-on-year decrease of 15.34%; profit attributable to shareholders was HK$14.704 billion, a year-on-year increase of 383.37%; earnings per share were HK$6.9, with an interim dividend proposed at HK$0.78 per share.
In the first half of 2026, the group's financial performance was outstanding, achieving an unaudited profit of HK$14.704 billion (2025: HK$3.042 billion), representing a 383% increase compared to the same period last year, primarily benefiting from the group's sale of its interests in UK Power Networks (UKPN) and UK Rails. The group seized the opportunity to realize these projects at favorable valuations, resulting in substantial accounting and cash gains, providing ample funds for future investments.
The global operational and investment environment remains challenging, with escalating geopolitical tensions and persistent inflationary pressures. However, POWER ASSETS has continued to demonstrate resilience in this uncertain environment, with a diversified business portfolio showing steady performance. The strategy of focusing on regulated asset investments has brought stable and reliable returns.
A solid financial foundation is a key pillar of POWER ASSETS' core strategy for sustained growth. S&P Global Ratings continues to grant the group a credit rating of "A/Stable." As of June 30, 2026, the group's net cash level stood at HK$42.505 billion, equipping us with substantial strength to face future challenges, explore new growth opportunities, and seek quality acquisition projects in accordance with investment criteria.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

SOLIS HOLDINGS (02227) intends to sell bonds for 253,000 Singapore dollars.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

SOLIS HOLDINGS (02227) intends to sell bonds for 253,000 Singapore dollars.

RECOMMEND





